On-Demand Video Session
Recorded from 2017 Western Pharmacy Exchange
Janice Hoffman, PharmD, Western University of Health Sciences
By the year 2050, the literature estimates a surge of patients with Alzheimer’s-type dementia to be more than 135 million in the United States. Currently, there are only a handful of agents approved for the treatment of Alzheimer’s Dementia. Research has identified several targeted hypothesis for new drug development. In 2017-18 there are likely 2 to 4 agents that will be added to the marketplace for the treatment of Alzheimer’s Disease including a vaccine to decrease Tau protein in the brain and a monoclonal antibody to decrease beta-amyloid deposits.
At the completion of this activity, the participant will be able to:
- Identify the 6 types of Dementia.
- Compare and contrast the currently available medications to the prosed new agents.
- Explain the proposed agents benefits to the therapy arsenal for Alzheimers.
Continuing Pharmacy Education
The California Pharmacists Association (#0113) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Upon completing an evaluation form, participants will be awarded 1.25 hours (0.125 CEUs) of Continuing Pharmacy Education Credit. A statement of credit will not be issued. Participants may log onto the CPE monitor website using their individual log in to download their statement of credit. Please allow 4 weeks for processing of CPE credits to the CPE monitor. UAN: 0113-0000-17-006-H04-P, 0113-0000-17-006-H04-T
Activity Type: Knowledge-based
Target Audience: Pharmacists and Technicians in all practice settings
Release Date: 1/5/2017
Expiration Date: 1/5/2020
CPhA Member – $49
Non-member – $99
|2017 Western Pharmacy Exchange Bundle Deal: $300
This session is one of 11 sessions in the bundle deal.
Purchase Bundle >